Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-three research firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $157.95.

Several equities research analysts recently weighed in on SRPT shares. Deutsche Bank Aktiengesellschaft decreased their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a report on Wednesday, March 19th. Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday, April 11th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and cut their price objective for the stock from $161.00 to $87.00 in a report on Monday, March 31st. Scotiabank reduced their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Wednesday, April 16th.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System grew its holdings in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after acquiring an additional 100 shares during the period. EP Wealth Advisors LLC boosted its position in shares of Sarepta Therapeutics by 2.2% during the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares during the last quarter. Manchester Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. UMB Bank n.a. grew its position in Sarepta Therapeutics by 36.0% in the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 138 shares during the period. Finally, CIBC Asset Management Inc grew its holdings in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $63.66 on Tuesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a fifty day simple moving average of $71.99 and a two-hundred day simple moving average of $102.96. Sarepta Therapeutics has a 1-year low of $48.01 and a 1-year high of $173.25. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of 50.93 and a beta of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.